Caris Life Sciences, Inc.
Caris Life Sciences, Inc.（CAI）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
cai · 股价预测 · 7 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 7 位华尔街分析师
Buy
7 位分析师
共识
评级分布
12 个月目标价
High
$38.00
Consensus
$28.60
+71.3% upside
Low
$21.00
Median: $30 · Last Close: $16.70
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$28.60
71.3% upside
High Target
$38
127.6%
Low Target
$21
25.8%
Current Price
$16.70
as of today
Based on analyst price targets, the CAI stock price prediction for the next 12 months ranges from $21 to $38. The consensus CAI price forecast of $28.60 implies 71.3% upside from the current price of $16.70.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $17.13 | ↑ 2.56% |
1-day model range: $16.94–$17.31. Peak: $17.31 (+2.56%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CAI · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-08 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-05-08 | BTIG | Maintains | Buy→Buy |
| 2026-05-08 | Citigroup | Maintains | Buy→Buy |
| 2026-04-06 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2026-03-13 | Canaccord Genuity | Maintains | Hold→Hold |
| 2026-02-27 | BTIG | Maintains | Buy→Buy |
| 2026-02-27 | Baird | Maintains | Outperform→Outperform |
| 2026-02-27 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2025-12-22 | Canaccord Genuity | Maintains | Hold→Hold |
| 2025-08-13 | Guggenheim | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Caris Life Sciences, Inc. (CAI) stock. Of the recent 12 rating actions, 0 were upgrades and 0 were downgrades. 7 analysts currently cover CAI.
分析师推荐趋势
CAI analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 3 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$1.0B
↓ 28.2% YoY
Revenue Next Year
$1.2B
↑ 19.9% YoY
EPS This Year
$0.13
EPS Next Year
$0.36
↑ 168.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast CAI EPS of $0.13 for the current fiscal year, based on estimates from 8 analysts. The CAI revenue forecast is $1.0B for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
CAI 股价预测由两类独立数据源支撑：来自 7 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。CAI 的共识目标价为 $28.60（+71.3% 上行空间），分析师共识为 Buy。
CAI 的短期预测（明日）为 $17.13（+2.56%）。
Caris Life Sciences, Inc. 在 NASDAQ 上市，代码 CAI。CAI 在 2027 年的整体展望偏积极，在覆盖分析师中约 86% 对应 Buy 共识。
常见问题
CAI 预测 · 8 个问题根据 7 位华尔街分析师，CAI 的 12 个月平均目标价为 $28.60，最高 $38.00、最低 $21.00。若有图表，中位目标价可在上方查看。相对当前价 $16.70，隐含约 +71.3% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.